Millennium Management LLC Has $1.97 Million Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Millennium Management LLC raised its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 160.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 90,436 shares of the company's stock after buying an additional 55,682 shares during the quarter. Millennium Management LLC owned about 0.31% of Dianthus Therapeutics worth $1,972,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $35,000. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $59,000. Finally, AlphaQuest LLC grew its holdings in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after purchasing an additional 3,072 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Trading Up 2.1%

NASDAQ:DNTH traded up $0.37 during mid-day trading on Wednesday, hitting $17.96. 160,469 shares of the company's stock were exchanged, compared to its average volume of 275,745. The company has a 50 day simple moving average of $18.89 and a 200-day simple moving average of $21.32. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The firm has a market capitalization of $577.59 million, a P/E ratio of -7.18 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on DNTH. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average price target of $53.00.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.